Real-World Clinical Outcomes of Azacitidine Versus Best Supportive Care in Higher-Risk Myelodysplastic Neoplasms: A Single-Center Cohort Study

<b>Background</b>: Higher-risk myelodysplastic neoplasms (HR-MDS) are associated with poor survival and a substantial risk of leukemic transformation. Although azacitidine is a standard treatment in this setting, comparative real-world data remain limited. We evaluated the association between azacit...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Mihai-Emilian Lapadat, Oana Stanca, Irina Nicoleta Triantafyllidis, Anca Mariana Ciobanu, Nicoleta Mariana Berbec, Cristina Negotei, Cristian Tudor Barta, Ana Maria Bordea, Madalina Marilena Oprea, Andrei Colita
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2026-04-01
Edice:	Medical Sciences
Témata:	higher-risk myelodysplastic neoplasms azacitidine hypomethylating agents overall survival leukemic transformation IPSS-R
On-line přístup:	https://www.mdpi.com/2076-3271/14/2/212
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!